Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment

Shinya Maekawa; Shinichi Takano; Nobuyuki Enomoto

doi:10.1016/j.jfma.2024.01.015

Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment

J Formos Med Assoc. 2024 Jan 19:S0929-6646(24)00048-2. doi: 10.1016/j.jfma.2024.01.015. Online ahead of print.

Authors

Shinya Maekawa¹, Shinichi Takano², Nobuyuki Enomoto²

Affiliations

¹ Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. Electronic address: maekawa@yamanashi.ac.jp.
² Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

PMID: 38245398
DOI: 10.1016/j.jfma.2024.01.015

Abstract

The advent of direct-acting antiviral (DAA) therapy has revolutionized hepatitis C virus (HCV) treatment, enabling most HCV-infected patients to achieve a sustained viral response (SVR) easily and safely in a short period. On the other hand, it is gradually being recognized that a significant proportion of patients are still at risk of developing de novo and recurrent hepatocellular carcinoma (HCC), even after HCV elimination, and therefore, elucidation of the risk of de novo and recurrent HCC, investigation of its molecular basis, and construction of accurate prediction models are emerging as new important clinical topics. In this review, we present recent advances regarding these issues.

Publication types

Review